Early studies suggest that these assays may have important clinical biomarker utility, as increased levels of circulating CK18 may be prognostic and/or predict tumour response to chemotherapy in a number of different solid tumours (Steele et al, 2008; Scott et al, 2009). Here, KRT18 is linked to neoplasm.